Pipeline

Development status (JP)

Please scroll horizontally to check

Development stage	Code name,generic name	Indication	Origin	Development	Remarks
Filed	AK1820 (isavuconazonium sulfate)	Aspergillosis, Mucormycosis and Cryptococcosis	Licensed：Basilea Pharmaceutica International Ltd, Allschwil	Asahi Kasei Pharma Corporation	Additional formulation
Phase III	TA799, apraglutide	Short bowel syndrome	Licensed: VectivBio AG, an Ironwood Pharmaceuticals subsidiary	VectivBio AG, an Ironwood Pharmaceuticals subsidiary	Phase I in Japan was conducted by Asahi Kasei Pharma
Phase II	ART-123, recombinant thrombomodulin alfa	Chemotherapy- induced peripheral neuropathy (CIPN)	In-house	Asahi Kasei Pharma Corporation and Veloxis Pharmaceuticals	Additional indication Joint U.S.-Japan Phase I study in progress
Phase II	AK1830	Pain associated with osteoarthritis Chronic low back pain	Licensed：Array BioPharma Inc., a wholly owned subsidiary of Pfizer, Inc.	Asahi Kasei Pharma Corporation
Phase I	AK1910	Autoimmune diseases	Licensed：SBI Biotech Co., Ltd.	Asahi Kasei Pharma Corporation

Development status (Global)

Please scroll horizontally to check

Development stage	Code name,generic name	Indication	Origin	Development	Region
Phase III	ART-123, recombinant thrombomodulin alfa	Severe sepsis with coagulopathy	In-house	Asahi Kasei Pharma Corporation	United States, Europe, etc.
Phase I	ART-123, recombinant thrombomodulin alfa	Chemotherapy- induced peripheral neuropathy (CIPN)	In-house	Asahi Kasei Pharma Corporation and Veloxis Pharmaceuticals	United States
Phase I	AK1320	Spinal fusion surgery	In-house	Asahi Kasei Pharma Corporation	North America

Development status (licensed out)

Please scroll horizontally to check

Development stage	Code name,generic name	Indication	Origin	Development	Region
Phase II	LY3857210	Chronic Pain	In-house (co-research with RaQualia Pharma Inc.)	Eli Lilly and Company	Global (AKP has rights to promote LY3857210 in Japan and China)